We conducted a test-negative case–control study based in five European sentinel surveillance networks. The early 2012/13 adjusted influenza vaccine effectiveness was 78.2% (95% CI: 18.0 to 94.2) against influenza B, 62.1% (95% CI: −22.9 to 88.3%) against A(H1)pdm09, 41.9 (95% CI: −67.1 to 79.8) against A(H3N2) and 50.4% (95% CI: −20.7 to 79.6) against all influenza types in the target groups for vaccination. Efforts to improve influenza vaccines should continue to better protect those at risk of severe illness or complications
BACKGROUND: In the third season of I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe), we...
BACKGROUND: In the third season of I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe), we...
A multicentre case-control study based on sentinel practitioner surveillance networks from seven Eur...
Baltazar Nunes: member of the I-MOVE case–control study teamWe conducted a test-negative case–contro...
To provide an early estimate of 2011/12 influenza vaccine effectiveness (VE), we conducted a multice...
We present early estimates (up to week 4 of 2011) of the 2010/11 seasonal influenza vaccine effectiv...
We conducted a test-negative case–control study based in five European sentinel surveillance network...
In the fifth season of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE), we undertook a...
In the fifth season of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE), we undertook a...
Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Ya...
Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Ya...
A multicentre case-control study based on sentinel practitioner surveillance networks from seven Eur...
Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Ya...
In the third season of I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe), we undertook a...
Within the Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) project we conducted a mult...
BACKGROUND: In the third season of I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe), we...
BACKGROUND: In the third season of I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe), we...
A multicentre case-control study based on sentinel practitioner surveillance networks from seven Eur...
Baltazar Nunes: member of the I-MOVE case–control study teamWe conducted a test-negative case–contro...
To provide an early estimate of 2011/12 influenza vaccine effectiveness (VE), we conducted a multice...
We present early estimates (up to week 4 of 2011) of the 2010/11 seasonal influenza vaccine effectiv...
We conducted a test-negative case–control study based in five European sentinel surveillance network...
In the fifth season of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE), we undertook a...
In the fifth season of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE), we undertook a...
Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Ya...
Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Ya...
A multicentre case-control study based on sentinel practitioner surveillance networks from seven Eur...
Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Ya...
In the third season of I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe), we undertook a...
Within the Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) project we conducted a mult...
BACKGROUND: In the third season of I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe), we...
BACKGROUND: In the third season of I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe), we...
A multicentre case-control study based on sentinel practitioner surveillance networks from seven Eur...